[Recurrent bronchitis and exertional dyspnea. Left-sided endobronchial tumor].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
V Ninane
Publications and source records attributed to V Ninane.
EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
BACKGROUND: The relationships between EGF-R and c-erbB-2 with other factors involved in tumour regulation are not well understood. The aim of this study was to correlate the expression of these markers with tumour proliferation. MATERIALS AND METHODS: The presence of EGF-R, c-erbB-2 and Ki-67 was evaluated by immunohistochemistry in non-small cell lung cancer (NSCLC) and preneoplastic lesions. RESULTS: Forty-two percent of the tumours were positive for EGF-R, 22% for c-erbB-2 and 97% for Ki-67. No statistically significant correlation was found between EGF-R and Ki-67, EGF-R and c-erbB-2 or between c-erbB-2 and Ki-67. With regards to Ki-67, a significant difference in survival was noted in favour of patients who did not express the marker. In preneoplastic lesions, most of the low-grade lesions showed neither EGF-R nor Ki-67 staining. In contrast, most of the high-grade lesions stained positively for these proteins. CONCLUSION: EGF-R and c-erbB-2 do not seem to be correlated with Ki-67 in NSCLC.
Adult↗
[Endoscopic treatment of bronchial cancer].
Endobronchial treatment plays a growing role in the treatment of bronchial carcinoma and other tracheobronchial tumours. Most patients are treated for the palliation of dyspnea or hemoptysis caused by a tumour located in a major airway. Different modalities are available for palliation including the neodymium YAG laser, endobronchial stents, cryotherapy and brachytherapy. Among other factors, the choice of the best modality or combination of techniques will depend on the degree of emergency and the characteristics of the tumour. Total ablation of small bronchial tumours (mainly at the in situ stage) can also be achieved, mainly by the means of photodynamic therapy. These different modalities, their indications and limitations in the treatment of tracheobronchial malignancies are discussed.
Brachytherapy↗